Clear Street’s NeuroSense Therapeutics NRSN Stock Holding History

Clear Street’s Portfolio NRSN Stock Details NRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-7,157	Closed	-$24K	–	1214
2022 Q2	$24K	Buy	+7,157	New	+$13.6K	﹤0.01%	372

Other funds holding NRSN

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VPIM

Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Clear Street's NRSN Position: Q3 2022 in Review

Clear Street sold out of NeuroSense Therapeutics (NRSN) in Q3 2022, closing a stake of 7,157 shares — an estimated $24K sold.

Clear Street first reported a position in NRSN in Q2 2022 and held it in 1 quarter. The position peaked at $24K in Q2 2022. 5 funds tracked by Wall St. Rank hold NRSN as of Q3 2022.

Clear Street reported no remaining NeuroSense Therapeutics position as of Q3 2022 after selling out during the quarter.
Clear Street sold 7,157 NeuroSense Therapeutics shares in Q3 2022, an estimated $24K.
Clear Street first reported a position in NeuroSense Therapeutics in Q2 2022 and held it in 1 quarter.
Clear Street's NeuroSense Therapeutics position peaked at $24K in Q2 2022.
5 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q3 2022.

Based on Clear Street's 13F filing for Q3 2022, filed 2 Nov 2022.